At Lyra, we are advancing leading-edge science to develop therapeutics that can make a positive impact on the lives of millions of patients.
Here are some of the ways we are making a difference for patients, for new therapeutic products, and for our community.
Lyra supports a diverse workplace and celebrates the company’s women executives and managers on International Women’s Day. We are proud to have our CEO Maria Palasis as a frequent speaker on the topic of women in science and industry.
Working with a team of researchers with global expertise, Lyra and Richard Douglas, M.D., Professor of Surgery at The University of Auckland, New Zealand, and Consultant Surgeon at Auckland City Hospital, publish Phase 1 clinical data for the company’s lead therapeutic, LYR210, for chronic rhinosinusitis (CRS), in the International Forum of Allergy & Rhinology [Publication]